Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised study
- DOI
- 10.1016/j.ero.2025.12.010
- Published
- 2026-03
- Container
- EULAR Rheumatology Open
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ero.2025.12.010,
title = {Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised study},
author = {Hiroaki Matsuno and Ernest Choy and Paul Emery and Masato Okada and Roshan Dias and Károly Horvát-Karajz and Gordana Dancer and Yusuke Karibe and Suguru Masuda and Joachim Kiefer and Gerd R Burmester},
year = {2026},
journal = {EULAR Rheumatology Open},
doi = {10.1016/j.ero.2025.12.010},
url = {https://doi.org/10.1016/j.ero.2025.12.010}
}RIS
TY - JOUR TI - Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised study AU - Hiroaki Matsuno AU - Ernest Choy AU - Paul Emery AU - Masato Okada AU - Roshan Dias AU - Károly Horvát-Karajz AU - Gordana Dancer AU - Yusuke Karibe AU - Suguru Masuda AU - Joachim Kiefer AU - Gerd R Burmester PY - 2026 JO - EULAR Rheumatology Open DO - 10.1016/j.ero.2025.12.010 UR - https://doi.org/10.1016/j.ero.2025.12.010 ER -
APA
Matsuno, H., Choy, E., Emery, P., Okada, M., Dias, R., Horvát-Karajz, K., Dancer, G., Karibe, Y., Masuda, S., Kiefer, J., & Burmester, G. R. (2026). Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised study. EULAR Rheumatology Open. https://doi.org/10.1016/j.ero.2025.12.010
Source records
- crossref · retrieved 2026-09-26T23:34:55.292Z